window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 23, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

FOLFOX

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Pierre Fabre wins EU approval for first-line BRAFTOVI regimen in BRAF-mutant colorectal cancer

    The European Commission has approved BRAFTOVI in combination with cetuximab [...]

    June 22, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Pierre Fabre moves closer to first-line approval for BRAFTOVI in BRAF-mutant metastatic colorectal cancer

    Pierre Fabre Laboratories has received a positive opinion from the [...]

    June 6, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Lubrizol excipient recognised at CPhI China Pharma Excipients Awards
    Categories: Drug Delivery & Formulation
  • AI adoption grows in life science labs but data integration remains a barrier, survey finds
    Categories: Digital & Data
  • Olorofim meets primary endpoint in phase 3 OASIS aspergillosis study
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top